AAminove
Back to library

CJC-1295

Animal / preclinicalWADA prohibited

Also known as: with DAC, Mod GRF (1-29)

Growth-hormone secretagoguesGH-releasing hormone analogue (claimed)

Community-reported ranges are anecdotal and not clinically validated. Evidence grade shown reflects the strength of available human data. Not a prescription. Legal status varies by country and changes over time; verify locally.

Overview

A growth-hormone-releasing-hormone analogue often paired with ipamorelin. Human evidence for the marketed benefits is limited.

Mechanism

Analogue of GHRH that stimulates pituitary GH release; DAC variants extend half-life.

Evidence

Animal / preclinicalWhat does this mean?

Limited human pharmacology data; efficacy for physique claims unproven.

Community-reported information

Community reports vary. Anecdotal and unvalidated; general information only.

General information only, not tailored to you and not a recommendation. Some regions withhold this entirely.

Half-life

Days (DAC variant); shorter without DAC.

Storage

Refrigerate lyophilised and reconstituted.

Commonly reported side effects

  • Flushing
  • Water retention
  • Injection-site reactions

Legal status by region

  • USNot FDA-approved for human use.
  • AUPrescription-only; import controlled.

Legal status changes over time; verify locally before relying on this.

Citations